


SUPPLEMENTARY MATERIAL

Supplementary Table 1 Anti-Parkinson's disease medication name and corresponding PBS code

Medication	PBS code	Dosage or Strength
Levodopa + carbidopa	1242J, 1245M, 1255C, 8970D, 9743T, 9744W	Levodopa (100 - 250 mg) + carbidopa (25 - 50 mg)
Levodopa + benserazide	2225D, 2226E, 2227F, 2228G, 2229H, 2231K, 8218M, 8219N	Levodopa (50 - 200 mg) + benserazide (12.5 - 50 mg)
Levodopa + carbidopa + entacapone	8797B, 8798C, 8799D, 9292C, 9344T, 9345W	Levodopa (50 - 200 mg) + carbidopa (12.5 - 50 mg) + entacapone (200 mg)
Amantadine hydrochloride	3016R	100 mg
Apomorphine hydrochloride hemihydrate	10950H, 10971K, 11083H, 11093W, 5609F, 5610G, 9607P, 9640J	10 mg/1 ml injection
Cabergoline	8393R, 8394T	500 µg – 2 mg
Pramipexole dihydrochloride monohydrate	3418X, 3419Y, 3420B, 3421C, 3422D, 5143Q, 5145T, 9151P, 9152Q, 9153R, 9393J, 9394K	125 µg – 4 mg
Rotigotine	1140H, 2384L, 2385M, 2410W	2 – 8 mg/24 hours
Benzatropine mesilate	11249C, 11255J, 11265X, 2362H	2 mg tablets, 2 mg/mL injection
Trihexyphenidyl (benzhexol) hydrochloride	1109J, 1110K	2 – 5 mg
Rasagiline	1952R	1 mg

Supplementary Table 2 APGS Invitations and respondents per state or territory of Australia

State or Territory	Letters sent by state N (%)	Respondents by state N (%)
New South Wales	6280 (31.1)	6160 (30.2)
Victoria	5020 (25.1)	4440 (22.2)
Queensland	4220 (21.1)	4860 (24.3)
South Australia	1880 (9.4)	1880 (9.4)
Western Australia	1740 (8.7)	1860 (9.3)
Tasmania	640 (3.2)	460 (2.3)
Australian Capital Territory	220 (1.1)	340 (1.7)
Northern Territory	0.3	0.6

Supplementary Figure 1 Male sample age distribution in APGS**Supplementary Figure 2** Female sample age distribution in APGS